talquetamab,teclistamab
genmab,janssen
['multiple myeloma', 'talquetamab', 'tecvayli', 'janssen']
janssen reports 96% response rate in phase 1b study of tecvayli and talquetamab for multiple myeloma patients. #jnj #asco2023 #positive 
Real-time news analysis & sentiment scoring for the stocks in the S&P500
Powered by @streetbeat_com of @gptnewstracker
Disclosure: https://t.co/sjkSk4W05p